Introducing the BÜHLMANN Calprotectin Assay Site

Gastroenterology Research is our Focus, Quality is our Standard, and Flexible Innovative Solutions are our Mission.

Take a closer look and learn full circle about IBD here with BÜHLMANN. The BÜHLMANN Calprotectin Assay product line has a range of solutions that services all types of users, from the subject's home test to the high throughput labs running thousands of samples. We have a variety of test formats to best suit your needs and no matter which assay you choose results are reliable, accurate, and consistent across all the board.

Introducing New Health Canada Licences

BÜHLMANN Laboratories AG's Quantum Blue^® Infliximab, lateral flow assay for rapid quantification of Infliximab in Serum; IBDoc^®, the first in-vitro diagnostic home testing device measuring the inflammatory marker fecal calprotectin at home; as well as CALEX^® Cap Device for rapid stool extraction are now commercially available in Canada and are Health Canada licenced.

The Value of Calprotectin in Inflammatory Bowel Disease Monitoring

Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease of the gut, which presents with periods of inflammatory activity (flares) and quiescent phases (remission) as can be seen in many chronic diseases. IBD includes several different diseases; the two most important ones are Ulcerative Colitis (UC), with inflammation localized mostly in the colon, and Crohn's Disease (CD) which affects the entire gastrointestinal tract. The highest reported prevalence of IBD is in Europe (UC, 505 per 100,000 persons; CD, 322 per 100,000 persons) and North America (UC, 249 per 100,000 persons; CD, 319 per 100,000 persons) and affects people of all ethnicities¹ IBD is believed to be associated with industrialization of nations² and the incidence may be rising in developing nations as they become more industrialized³.

BÜHLMANN Calprotectin (fCAL) ELISA

BÜHLMANN GanglioCombi^™ MAG ELISA

Special Pricing for Select Assays and Allergens